Drugs / CHK336
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05367661 | Apr 2022 → Apr 2023 | — | Chinook Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHK-336 | “We identified CHK-336, a novel oral small-molecule that demonstrates potent and selective inhibition of the human LDH enzyme and its activity in hepatocyte assays across...” PMID 40193200 ↗ Apr 2025 |
| Action | Inhibit | “CHK-336 is a liver-targeted, small-molecule lactate dehydrogenase A inhibitor with potential to treat diseases associated with elevated oxalate production.” PMID 40193200 ↗ Apr 2025 |
| Modality | Small molecule | “CHK-336 is a liver-targeted, small-molecule lactate dehydrogenase A inhibitor with potential to treat diseases associated with elevated oxalate production.” PMID 40193200 ↗ Apr 2025 |
| Route | Oral | “We identified CHK-336, a novel oral small-molecule that demonstrates potent and selective inhibition of the human LDH enzyme and its activity in hepatocyte assays across...” PMID 40193200 ↗ Apr 2025 |